Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multi-Center, Randomized, Open-Label Study of PS-341 [bortezomib] (VELCADE) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Next Previous
Trial Profile

An International, Multi-Center, Randomized, Open-Label Study of PS-341 [bortezomib] (VELCADE) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms APEX
  • Sponsors Millennium

Most Recent Events

  • 13 Dec 2022 Results by deriving gene expression profiles from APEX; assessing whether increased expression of genes PSMC2 and PSMC6, correlated with poorer OS , presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 12 Jan 2012 Status of the extension trial (NCT00063726) is completed.
  • 12 Jan 2012 Status of the extension trial (NCT00063726) is completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top